Literature DB >> 12361895

Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.

K M C Verhamme1, J P Dieleman, G S Bleumink, J van der Lei, M C J M Sturkenboom, W Artibani, B Begaud, R Berges, A Borkowski, C R Chappel, A Costello, P Dobronski, R D T Farmer, F Jiménez Cruz, U Jonas, K MacRae, L Pientka, F F H Rutten, C P van Schayck, M J Speakman, M C Sturkenboom, P Tiellac, A Tubaro, G Vallencien, R Vela Navarrete.   

Abstract

OBJECTIVE: Benign prostatic hyperplasia (BPH) is one of the most common conditions associated with ageing in men. BPH often presents as lower urinary tract symptoms (LUTS) due to difficulties in voiding and irritability of the bladder. We conducted a retrospective cohort study within the Integrated Primary Care Information (IPCI) database, a general practitioners database in The Netherlands, to assess the incidence of LUTS suggestive of BPH (LUTS/BPH) in the general population. MATERIALS: Our study population comprised all males, 45 years or older who were registered for at least 6 months prior to start of follow-up. The study period lasted from 1 January 1995 to 31 December 2000. Cases of LUTS/BPH were defined as persons with a diagnosis of BPH, treatment or surgery for BPH, or urinary symptoms suggestive of BPH that could not be explained by other co-morbidity.
RESULTS: The study cohort comprised 80,774 males who contributed 141,035 person-years of follow-up. We identified 2181 incident and 5605 prevalent LUTS/BPH cases. The overall incidence rate of LUTS/BPH was 15 per 1000 man-years (95% CI: 14.8-16.1). The incidence increased linearly (r(2) = 0.99) with age from three cases per 1000 man-years at the age of 45-49 years (95% CI: 2.4-3.6) to a maximum of 38 cases per 1000 man-years at the age of 75-79 years (95% CI: 34.1-42.9). After the age of 80 years, the incidence rate remained constant. For a symptom-free man of 46 years, the risk to develop LUTS/BPH over the coming 30 years, if he survives, is 45%. The overall prevalence of LUTS/BPH was 10.3% (95% CI: 10.2-10.5). The prevalence rate was lowest among males 45-49 years of age (2.7%) and increased with age until a maximum at the age of 80 years (24%).
CONCLUSIONS: The incidence rate of LUTS/BPH increases linearly with age and reaches its maximum at the age of 79 years. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Year:  2002        PMID: 12361895     DOI: 10.1016/s0302-2838(02)00354-8

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  84 in total

Review 1.  Transurethral microwave thermotherapy for the treatment of BPH: still a challenger?

Authors:  T R W Herrmann; A J Gross; D Schultheiss; P M Kaufmann; U Jonas; M Burchardt
Journal:  World J Urol       Date:  2006-06-03       Impact factor: 4.226

2.  Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis.

Authors:  Zheng Deng; Menghao Sun; Yiping Zhu; Jian Zhuo; Fujun Zhao; Shujie Xia; Bangmin Han; Thomas R W Herrmann
Journal:  World J Urol       Date:  2018-04-12       Impact factor: 4.226

Review 3.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Authors:  David Ulmert; M Frank O'Brien; Anders S Bjartell; Hans Lilja
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

4.  Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.

Authors:  Amyn Sayani; Afisi Ismaila; Anna Walker; John Posnett; Bruno Laroche; J Curtis Nickel; Zhen Su
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

Review 5.  Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis.

Authors:  Yin Tang; Jinhong Li; Chuanxiao Pu; YunJin Bai; HaiChao Yuan; Qiang Wei; Ping Han
Journal:  J Endourol       Date:  2014-06-05       Impact factor: 2.942

6.  Prospective randomized study comparing monopolar with bipolar transurethral resection of prostate in benign prostatic obstruction: 36-month outcomes.

Authors:  Samer Fathi Al-Rawashdah; Antonio Luigi Pastore; Yazan Al Salhi; Andrea Fuschi; Vincenzo Petrozza; Angela Maurizi; Ester Illiano; Elisabetta Costantini; Giovanni Palleschi; Antonio Carbone
Journal:  World J Urol       Date:  2017-02-27       Impact factor: 4.226

7.  Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?

Authors:  Ferdinando Fusco; Davide Arcaniolo; Massimiliano Creta; Gaetano Piccinocchi; Giovanni Arpino; Matteo Laringe; Roberto Piccinocchi; Nicola Longo; Paolo Verze; Francesco Mangiapia; Vittorio Imperatore; Vincenzo Mirone
Journal:  World J Urol       Date:  2014-12-10       Impact factor: 4.226

8.  Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model.

Authors:  Mehrnaz Gharaee-Kermani; Jose A Rodriguez-Nieves; Rohit Mehra; Chad A Vezina; Aruna V Sarma; Jill A Macoska
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

9.  Metabolic syndrome in sub-Saharan Africa: "smaller twin" of a region's prostatic diseases?

Authors:  Chukwunonso E C C Ejike; Lawrence U S Ezeanyika
Journal:  Int Urol Nephrol       Date:  2008-02-21       Impact factor: 2.370

10.  Medical management of benign prostatic hyperplasia: Results from a population-based study.

Authors:  Mohamed Bishr; Katharina Boehm; Vincent Trudeau; Zhe Tian; Paolo Dell'Oglio; Jonas Schiffmann; Claudio Jeldres; Maxine Sun; Sharokh F Shariat; Markus Graefen; Fred Saad; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.